{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:38:09Z","timestamp":1766504289387,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008680","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008680","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-1-0648"],"award-info":[{"award-number":["W81XWH-18-1-0648"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.msard.2021.102910","type":"journal-article","created":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T11:01:43Z","timestamp":1616324503000},"page":"102910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Obesity is associated with the Optic Neuritis severity in Male patients with Multiple Sclerosis"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5649-0219","authenticated-orcid":false,"given":"Duong T.","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8521-4117","authenticated-orcid":false,"given":"Mattia","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy T.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrishti","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian C.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard L.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9897-4422","authenticated-orcid":false,"given":"Tanuja","family":"Chitnis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.102910_bib0001","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Disease","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.102910_bib0002","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.102910_bib0003","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1212\/WNL.0000000000001856","article-title":"Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis","volume":"85","author":"Novotna","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102910_bib0004","doi-asserted-by":"crossref","first-page":"393","DOI":"10.20344\/amp.4322","article-title":"Secondary progression is not the only explanation","volume":"27","author":"Palavra","year":"2014","journal-title":"Acta Med Port"},{"key":"10.1016\/j.msard.2021.102910_bib0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1474-4422(10)70094-6","article-title":"Multiple sclerosis: risk factors, prodromes, and potential causal pathways","volume":"9","author":"Ramagopalan","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2021.102910_bib0006","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3109\/00207454.2013.840618","article-title":"Epidemiology and clinical record of multiple sclerosis in selected countries: a systematic review","volume":"124","author":"Niedziela","year":"2014","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.msard.2021.102910_bib0007","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/1352458513519181","article-title":"The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis","volume":"20","author":"Bove","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2021.102910_bib0008","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/1352458517737395","article-title":"The role of testosterone in MS risk and course","volume":"24","author":"Chitnis","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2021.102910_bib0009","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1177\/1352458514527864","article-title":"Low testosterone is associated with disability in men with multiple sclerosis","volume":"20","author":"Bove","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2021.102910_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.msard.2021.102910_bib0011","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/ijo.2010.137","article-title":"C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian randomization","volume":"35","author":"Timpson","year":"2011","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.msard.2021.102910_bib0012","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1542\/peds.107.1.e13","article-title":"Low-grade systemic inflammation in overweight children","volume":"107","author":"Visser","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.msard.2021.102910_bib0013","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.2337\/diacare.26.10.2968","article-title":"The effect of weight loss on endothelial functions in obesity: response to Sciacqua et\u00a0al","volume":"26","author":"Esposito","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.msard.2021.102910_bib0014","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/sj.ijo.0801825","article-title":"Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals","volume":"25","author":"van Dielen","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.msard.2021.102910_bib0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.metabol.2014.10.014","article-title":"Leptin in autoimmune diseases","volume":"64","author":"Procaccini","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.msard.2021.102910_bib0016","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1073\/pnas.0408995102","article-title":"Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells","volume":"102","author":"Matarese","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.msard.2021.102910_bib0017","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/ajcn\/72.3.690","article-title":"Decreased bioavailability of vitamin D in obesity","volume":"72","author":"Wortsman","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.msard.2021.102910_bib0018","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/WNL.0b013e31828154f3","article-title":"Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome","volume":"80","author":"Langer-Gould","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102910_bib0019","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/obr.12363","article-title":"Obesity and brain inflammation: a focus on multiple sclerosis","volume":"17","author":"Palavra","year":"2016","journal-title":"Obes Rev"},{"key":"10.1016\/j.msard.2021.102910_bib0020","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1212\/WNL.0000000000000524","article-title":"Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis","volume":"82","author":"Malik","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102910_bib0021","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.autrev.2006.02.012","article-title":"A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study","volume":"5","author":"Gauthier","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.msard.2021.102910_bib0022","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2021.102910_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101384","article-title":"Adipokines are associated with pediatric multiple sclerosis risk and course","volume":"36","author":"Keyhanian","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2021.102910_bib0024","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","article-title":"Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.msard.2021.102910_bib0025","first-page":"616","article-title":"The Diagnosis and Treatment of Optic Neuritis","volume":"112","author":"Wilhelm","year":"2015","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.msard.2021.102910_bib0026","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1210\/jcem.84.10.6079","article-title":"A critical evaluation of simple methods for the estimation of free testosterone in serum","volume":"84","author":"Vermeulen","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.msard.2021.102910_bib0027","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2015.09.008","article-title":"Body mass index influence interferon-beta treatment response in multiple sclerosis","volume":"288","author":"Kvistad","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.msard.2021.102910_bib0028","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12974-018-1114-8","article-title":"Oxysterol levels and metabolism in the course of neuroinflammation: insights from in vitro and in vivo models","volume":"15","author":"Mutemberezi","year":"2018","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.msard.2021.102910_bib0029","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0079-6123(09)17516-7","article-title":"Estrogen and testosterone therapies in multiple sclerosis","volume":"175","author":"Gold","year":"2009","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.msard.2021.102910_bib0030","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1210\/er.2007-0001","article-title":"The complex role of estrogens in inflammation","volume":"28","author":"Straub","year":"2007","journal-title":"Endocr Rev"},{"key":"10.1016\/j.msard.2021.102910_bib0031","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4049\/jimmunol.158.1.446","article-title":"Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects","volume":"158","author":"Gilmore","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.msard.2021.102910_bib0032","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/imm.13004","article-title":"Impact of sex hormones on immune function and multiple sclerosis development","volume":"156","author":"Ysrraelit","year":"2019","journal-title":"Immunology"},{"key":"10.1016\/j.msard.2021.102910_bib0033","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamaneurol.2013.5993","article-title":"Vitamin D as an early predictor of multiple sclerosis activity and progression","volume":"71","author":"Ascherio","year":"2014","journal-title":"JAMA Neurol"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:56:34Z","timestamp":1761900994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821001772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":33,"alternative-id":["S2211034821001772"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102910","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity is associated with the Optic Neuritis severity in Male patients with Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102910"}}